Consensus on biomarkers for neuroendocrine tumour disease
Top Cited Papers
- 1 September 2015
- journal article
- review article
- Published by Elsevier BV in The Lancet Oncology
- Vol. 16 (9), e435-e446
- https://doi.org/10.1016/s1470-2045(15)00186-2
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Blood transcript analysis and metastatic recurrent small bowel carcinoid managementBMC Cancer, 2014
- Global microRNA profiling of well-differentiated small intestinal neuroendocrine tumorsLaboratory Investigation, 2013
- Molecular Profiling for Breast Cancer: A Comprehensive ReviewBiomarkers in Cancer, 2013
- An elevated progastrin-releasing peptide level in patients with well-differentiated neuroendocrine tumours indicates a primary tumour in the lung and predicts a shorter survivalAnnals Of Oncology, 2011
- Granin-derived peptides as diagnostic and prognostic markers for endocrine tumorsRegulatory Peptides, 2010
- Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE)Annals Of Oncology, 2010
- One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United StatesJournal of Clinical Oncology, 2008
- Measurements of chromogranin B can serve as a complement to chromogranin ARegulatory Peptides, 2006
- Serum peptide profiles in patients with carcinoid tumorsThe American Journal of Surgery, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000